Document is current
Any future updates will be listed below
-
Authors
Pan, Wen
Hunkler, Hannah J.
Chatterjee, Shambhabi
Lu, Dongchao
Riedel, Isabelle
Gietz, Anika
Xiao, Ke
Fuchs, Maximilian
Neufeldt, Dimyana
Kraft, Theresia
Huang, Cheng-Kai
Cushman, Sarah
Bührke, Anne
Schmidt, Arne
Mohr, Elisa
Weber, Natalie
Bär, Christian https://orcid.org/0000-0001-9276-9383
Thum, Thomas
-
Funding
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 25 February 2025
Revised: 3 September 2025
Accepted: 11 September 2025
First Online: 21 October 2025
Declarations
:
: T. T. is founder and CSO/CMO of Cardior Pharmaceuticals GmbH, a wholly-owned subsidiary of Novo Nordisk Europe A/S (outside of this study). T.T., D.L., C-K.H., A.B. and C.B. filed and partially licensed patents on non-coding RNAs for the treatment of cardiovascular diseases. All other authors declare that no conflict of interest exist.
